Subscribe To

Price Alert Latest News Economic Calendar News

CVRX / CVRx to Present at the William Blair 43rd Annual Growth Stock Conference

MINNEAPOLIS, May 25, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the William Blair 43rd Annual Growth Stock Conference on Thursday, June 8, 2023. The Company is scheduled to present at the conference at 9:20 am Central Time (10:20 am Eastern Time). A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com . About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. Investor Contact: Mark Klausner or Mike VallieICR Westwicke443-213-0501 [email protected] Media Contact: Laura O'NeillFinn Partners402-499-8203 [email protected] Read More

Demo Live Account See Partner Details

Content Topics

CVRX

Present

William

Blair

43rd

Annual

Growth

Stock

Conference

Posted: May 25 2023, 08:30

Author Name: GlobeNewsWire

CVRX News

By Zacks Investment Research
October 31, 2023

What Makes CVRx (CVRX) a New Strong Buy Stock

CVRx (CVRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive th

By Seeking Alpha
October 26, 2023

CVRx, Inc. (CVRX) Q3 2023 Earnings Call Transcript

CVRx, Inc. (NASDAQ:CVRX ) Q3 2023 Earnings Conference Call October 26, 2023 5:30 PM ET Company Participants Mike Vallie - SVP-ICR Westwicke Nadim Yare

By Seeking Alpha
September 3, 2023

CVRX: BeAT-HF Overhang Now Fully Dealt With, Upsides Now In Motion, Reiterate Buy

CVRx Inc's has recovered towards previous highs following the fallout of its BeAT-HF trial results in February 2023. Adoption and utilization of its B

By Seeking Alpha
July 25, 2023

CVRx, Inc. (CVRX) Q2 2023 Earnings Call Transcript

CVRx, Inc. (NASDAQ:CVRX ) Q2 2023 Earnings Conference Call July 25, 2023 5:30 PM ET Company Participants Mike Vallie – Senior Vice President-ICR Wes

By Zacks Investment Research
July 25, 2023

CVRx (CVRX) Reports Q2 Loss, Tops Revenue Estimates

CVRx (CVRX) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.54 p

By GlobeNewsWire
July 11, 2023

CVRx to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call on July 25th, 2023

MINNEAPOLIS, July 11, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing

By Zacks Investment Research
July 3, 2023

CVRx (CVRX) Surges 7.2%: Is This an Indication of Further Gains?

CVRx (CVRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions co

By Seeking Alpha
June 16, 2023

CVRx: Missing A Heartbeat

I called CVRx a highly risky but potentially lucrative investment at the time of the IPO in the summer of 2021. The company has seen solid revenue gro

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.